Clovis Upgraded On Takeover Potential As Pharma M&A Heats Up

Shares of Clovis Oncology are on the rise once again after Credit Suisse upgraded the stock to Outperform, a Buy-equivalent rating, with its analyst Kennen MacKay highlighting the company's potential as takeover target.